Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne's financial outlook reflects a stable revenue trajectory, with new estimates projecting revenues of $315.0 million, marking a 3% increase compared to the previous quarter. Additionally, the company's adjusted earnings are expected to rise to $0.50 per share, an improvement from $0.49 a year earlier. These metrics indicate a positive growth momentum in both revenue and earnings, contributing to a favorable view of Bio-Techne's stock performance.

Bears say

Bio-Techne is facing significant headwinds due to the escalation of U.S. tariffs and proposed funding cuts of up to 40% for key agencies such as the NIH, which are expected to negatively impact revenues and gross margins in the fourth quarter of fiscal year 2025. The company has adjusted its financial estimates for the upcoming quarter, anticipating slower-than-expected revenue growth and margin contraction. These challenges could hinder Bio-Techne’s financial performance, particularly given that a substantial portion of its revenue relies on U.S. sales and government funding for life sciences research.

Bio-Techne (TECH) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 12 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.